logo
#

Latest news with #profitMargin

Tsogo Sun Full Year 2025 Earnings: EPS: R1.20 (vs R1.47 in FY 2024)
Tsogo Sun Full Year 2025 Earnings: EPS: R1.20 (vs R1.47 in FY 2024)

Yahoo

time30-05-2025

  • Business
  • Yahoo

Tsogo Sun Full Year 2025 Earnings: EPS: R1.20 (vs R1.47 in FY 2024)

Revenue: R11.2b (down 2.5% from FY 2024). Net income: R1.24b (down 19% from FY 2024). Profit margin: 11% (down from 13% in FY 2024). EPS: R1.20 (down from R1.47 in FY 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 2.4% p.a. on average during the next 2 years, compared to a 2.5% growth forecast for the Hospitality industry in Africa. Performance of the market in South Africa. The company's shares are down 1.4% from a week ago. It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Tsogo Sun, and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

‘I don't apologise': Bunnings boss responds to ABC claims
‘I don't apologise': Bunnings boss responds to ABC claims

News.com.au

time26-05-2025

  • Business
  • News.com.au

‘I don't apologise': Bunnings boss responds to ABC claims

Wesfarmers chief executive Rob Scott has hit back at an ABC Four Corners documentary accusing Bunnings of pressuring suppliers, stifling competition and inflating prices, saying he 'does not apologise for trying to build a successful business'. The episode aired last week and put the beloved Australian hardware giant under scrutiny, highlighting supplier complaints and examining the chain's $19bn revenue and $3.2bn profit in 2024, figures that equate to a 16.8 per cent profit margin, nearly double that of supermarket giants Woolworths and Coles. Speaking on Sky News' Business Weekend, Mr Scott defended Bunnings' operations and rejected the suggestion that the company engaged in unfair practices. 'We pay our team members more than well above the award rates, the relationships we have with our thousands of suppliers are very strong and longstanding,' Mr Scott said. 'Now, occasionally, businesses make mistakes and when they do make a mistake, it's important that they own it and face into it.' Mr Scott also acknowledged that Bunnings' presence in certain retail precincts could put pressure on competitors but maintained this was ultimately a benefit to customers. 'There is pressure on the competition, but at the end of the day someone has to be there for the customer, right?' he said. 'Someone has to offer great value to customers and remembering as well that I don't apologise for trying to build a successful business in Bunnings.' He added that the company was contending with major global retailers and remained focused on maintaining local jobs and opportunities. 'We are fighting tooth and nail against some very big and fierce international competitors in the retail space and we would rather that those jobs and those opportunities stay within Bunnings,' he told Sky News. The ABC report also flagged concerns from suppliers who alleged the company marked up products significantly to boost profits, with critics claiming Bunnings' pricing strategy was misleading. In response, Bunnings said its margins weren't directly comparable with supermarkets because of the nature of its stock and slower product turnover. Bunnings' business practices are also expected to come under further scrutiny as part of a federal Senate inquiry into the market power of so-called 'big box' retailers, including Ikea and Costco. In a statement following the Four Corners broadcast, Bunnings managing director Mike Schneider said the company 'strongly rejects any suggestions made in the program that we engage in anti-competitive behaviour, bullying, underpayment of our team or that we seek to limit consumer choice or the application of our price guarantee. 'We want to reaffirm our commitment to the values that have guided our business for decades which is in direct contrast to the characterisations made by the ABC.'

RHÖN-KLINIKUM First Quarter 2025 Earnings: EPS: €0.11 (vs €0.16 in 1Q 2024)
RHÖN-KLINIKUM First Quarter 2025 Earnings: EPS: €0.11 (vs €0.16 in 1Q 2024)

Yahoo

time10-05-2025

  • Business
  • Yahoo

RHÖN-KLINIKUM First Quarter 2025 Earnings: EPS: €0.11 (vs €0.16 in 1Q 2024)

Revenue: €479.9m (up 5.3% from 1Q 2024). Net income: €7.14m (down 34% from 1Q 2024). Profit margin: 1.5% (down from 2.4% in 1Q 2024). The decrease in margin was driven by higher expenses. EPS: €0.11 (down from €0.16 in 1Q 2024). We check all companies for important risks. See what we found for RHÖN-KLINIKUM in our free report. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is expected to decline by 9.1% p.a. on average during the next 2 years, while revenues in the Healthcare industry in Germany are expected to grow by 4.0%. Performance of the German Healthcare industry. The company's shares are down 12% from a week ago. While earnings are important, another area to consider is the balance sheet. See our latest analysis on RHÖN-KLINIKUM's balance sheet health. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store